William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD) today. The company’s shares opened today at $19.80.
Prasad commented:
“We continue to view 2019 as a pivotal year for Celyad, including roughly 30 patients treated with CY AD-01 and key go-no-go decisions and dose optimization anticipated by year-end. In our view , the most near-term catalyst will be a presentation of clinical data from the Phase I SHRINK and alloSHRINK trials evaluating CY AD-01 and CY AD-101, respectively , at the Oncology (ESMO) Cancer (WCGIC), which will be held July 3-6. The presentation will provide a novel perspective on an allogeneic (CY AD-101) versus autologous (CY AD-01) approach as both candidates use the same NKG2D CAR construct to target same indication (metastatic colorectal cancer [mCRC]).”
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 19.3% and a 56.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Logicbio Therapeutics Inc, and Allogene Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Celyad with a $51 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.18 and a one-year low of $15.36. Currently, Celyad has an average volume of 3,472.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.
